Physician profile
Jamie P Dickerhoff
NPI 1386970572
$4,883.14
in general payments reported to CMS, 2019-2025
26 companies · $34.43 in 2025
The $34.43 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $1,191 · 2023: $1,654 · 2024: $1,721 · 2025: $34.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,003.71 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $774.19 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $608.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $518.45 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $324.08 | 2022-2024 | |
| Exact Sciences Corporation | $301.64 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.11 | 2021-2024 | Jardiance |
| Almatica Pharma LLC | $173.51 | 2024 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $131.79 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.06 | 2022-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $94.86 | 2021-2022 | |
| Abbott Laboratories | $78.40 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Glaxosmithkline, LLC. | $78.04 | 2022-2023 | Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $70.45 | 2022 | |
| Ironwood Pharmaceuticals, INC | $65.19 | 2022-2024 | Linzess |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.39 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $49.14 | 2021-2022 | |
| Amgen INC. | $46.26 | 2022-2024 | Repatha, Otezla |
| Horizon Therapeutics Plc | $40.30 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.16 | 2024 | Caplyta |
| Hologic Sales and Service, LLC | $31.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.49 | 2024 | Voquezna |
| Myovant Sciences INC. | $24.89 | 2022 | |
| Dexcom, INC. | $19.66 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $18.29 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Idorsia Pharmaceuticals US INC | $12.86 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Dickerhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.